CytomX Therapeutics (CTMX) Free Cash Flow Growth (1y) (2015 - 2026)
CytomX Therapeutics (CTMX) Free Cash Flow Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,801.52 Bn | 66,801.23 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 472.27 Bn | 467.47 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 122.18 Bn | 114.93 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 70.08 Bn | 61.32 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.86 Bn | 50.68 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 137.65% |
| 10 | CytomX Therapeutics | 591.21 Mn | 244.50 Mn | - | -20.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -20.73% |
| Dec 31, 2025 | -17.29% |
| Sep 30, 2025 | 25.67% |
| Jun 30, 2025 | 19.67% |
| Mar 31, 2025 | 19.11% |
| Dec 31, 2024 | 6.88% |
| Sep 30, 2024 | -13.68% |
| Jun 30, 2024 | 23.55% |
| Mar 31, 2024 | -381.26% |
| Dec 31, 2023 | -1,262.79% |
| Sep 30, 2023 | 46.72% |
| Jun 30, 2023 | 25.84% |
| Mar 31, 2023 | 122.12% |
| Dec 31, 2022 | 94.99% |
| Sep 30, 2022 | -14.31% |
| Jun 30, 2022 | -22.38% |
| Mar 31, 2022 | -35.98% |
| Dec 31, 2021 | -100.43% |
| Sep 30, 2021 | -17.72% |
| Jun 30, 2021 | -129.17% |